**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 10089**

**Columns:** **TOPIC HIGHLIGHTS**

**WJG 20th Anniversary Special Issues (1): Hepatocellular carcinoma**

**Safety of hepatectomy for elderly patients with hepatocellular carcinoma**

Oishi K *et al.* Hepatectomy for elderly HCC patients

Koichi Oishi, Toshiyuki Itamoto, Toshihiko Kohashi, Yasuhiro Matsugu, Hideki Nakahara, Mikiya Kitamoto

**Koichi Oishi, Toshiyuki Itamoto, Toshihiko Kohashi, Yasuhiro Matsugu, Hideki Nakahara,** Department of Gastroenterological Surgery, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan

**Toshiyuki Itamoto,** Faculty of Medicine, Hiroshima University, 1–2–3 Kasumi, Minami-ku, 1-5-54 Ujina-Kanda, Minami-ku, Hiroshima 734-0037, Japan

**Mikiya Kitamoto,** Department of Hepatology, Hiroshima Prefectural Hospital, Hiroshima, 1-5-54 Ujina-Kanda, Minami-ku 734-8530, Japan

**Author contributions:** Oishi K, Itamoto T, Kohashi T, Matsugu Y, Nakahara H and Kitamoto M analyzed the data; Oishi K and Itamoto T wrote the paper.

**Correspondence to:** **Koichi Oishi, MD,** Department of Gastroenterological Surgery, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda Minami-ku, Hiroshima 734-8530, Japan. koishi@enjoy.ne.jp

**Telephone:** +81-82-2541818 **Fax:** +81-82-2538274

**Received:** March 12, 2014 **Revised:** May 11, 2014

**Accepted:** July 22, 2014

**Published online:**

**Abstract**

The number of elderly patients with hepatocellular carcinoma (HCC) has been increasing. Characteristics of elderly HCC patients are a higher proportion of females, lower rate of positive hepatitis B surface antigen and higher rate of positive hepatitis C antibody. Careful patient selection is the key for performing hepatectomy safely in elderly HCC patients. Treatment strategy should be decided by considering not only tumor stage and hepatic functional reserve but also physiological status including comorbid disease. Various assessment tools have been applied to predict the risk of hepatectomy. The reported mortality and morbidity rates after hepatectomy in elderly HCC patients ranged from 0% to 42.9% and from 9% to 51%, respectively. Overall survival rate after hepatectomy in elderly HCC patients at 5 years ranged from 26% to 75.9%. Both short-term and long-term results after hepatectomy for strictly selected elderly HCC patients are almost the same as those for younger patients. However, considering physiological characteristics and high prevalence of comorbid disease in elderly patients, it is important to assess patients more meticulously and to select patients strictly if scheduled to undergo major hepatectomy.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words**: Hepatocellular carcinoma; Hepatectomy; Elderly

**Core tip**: The number of elderly patients with hepatocellular carcinoma (HCC) has been increasing. Careful patient selection is the key for performing hepatectomy safely in elderly HCC patients. Treatment strategy should be decided by considering not only tumor stage and hepatic functional reserve but also physiological status including comorbid disease. Both short-term and long-term results after hepatectomy for strictly selected elderly HCC patients are almost the same as those for younger patients. However, considering physiological characteristics and high prevalence of comorbid disease in elderly patients, it is important to assess patients more meticulously if scheduled to undergo major hepatectomy.

Oishi K, Itamoto T, Kohashi T, Matsugu Y, Nakahara H, Kitamoto M. Safety of hepatectomy for elderly patients with hepatocellular carcinoma. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the third leading cause of death worldwide. Age-standardized incidence rates in Eastern Asia are 35.5 per 100000 in males and 12.7 per 100000 in females. An estimated 748300 new liver cancer cases and 695900 cancer deaths occurred worldwide in 2008[1]. Hepatitis B virus (HBV) infection or hepatitis C virus (HCV) infection is recognized as the major risk factor for development of HCC. In fact, it has been estimated that HBV infection is associated with 50%–80% of HCC cases worldwide, whereas HCV infection is implicated in the pathogenesis of 10%–25% of HCC cases. The incidence of HCC in the cirrhotic liver associated with HBV or HCV infection is between 1% and 7% per year. Another cause of cirrhosis in which HCC can develop is alcohol abuse. Non-alcoholic steatohepatitis-related cirrhosis is also a risk factor for the development of HCC. A recent study has suggested that aging itself might be a factor affecting hepatocarcinogenesis[2].

The average life expectancy at birth has been increasing worldwide. In Japan, 75-year-old men and women have average expected life spans of around 5 and 10 years, respectively. An 80-year-old male has an average life expectancy of 8.26 years, while a female aged 80 years can expect to live another 11.04 years[3].

The number of elderly HCC patients has been increasing[4, 5]. The average age of HCC patients and the proportion of elderly HCC patients in Japan are increasing. A recent report showed that the mean ages at diagnosis of HCC were 66.4 years in males and 69.9 years in females[6]. Another recent report showed that patients over 70 years of age constitute more than 50% of those undergoing hepatectomy for HCC[7]. HCC is considered to be a life-limiting factor even in very old patients. Therefore, in patients with good liver function and good performance status (PS), hepatectomy for HCC might improve the survival rate, even in very old patients[8]. Aging causes several problems due to decline in the functional reserve of multiple organ systems and high prevalence of comorbidity in the treatment of HCC.

This review summaries the physiology, characteristics, preoperative risk assessment, and clinical outcomes in elderly HCC patients undergoing hepatectomy.

**DEFINITION OF ELDERLY**

The “elderly” is not clearly defined as a homogeneous population because different age subsets that are divided with ages ranging from 65 to 80 years are mixed. Elderly individuals have been defined in reports as individuals of 65, 70, 75 or 80 years of age and older. Elderly HCC patients were defined as patients of 70 years of age and older in most reports before 2010[9-15]. However, due to the change to a more aged society, reports in which elderly HCC patients are defined as patients of 75 years of age and older have been increasing in recent years[16-21]. Caratozzolo *et al*[22].reported that the cutoff age related to complications after hepatectomy was 75 years However, there have been a few reports in which elderly HCC patients are defined as patients of 80 years of age and older[23-25]. At present, a definition of elderly as 75 years of age and older is appropriate. However, due to the advance to a more aged society in the near future, a definition of elderly as 80 years of age and older will become appropriate.

**PHYSIOLOGICAL ALTERATION OF THE LIVER CAUSED BY AGING**

Aging changes biological functions in many organs. Several vital proteins such as albumin, prothrombin and fibrinogen are produced in the liver. Albumin maintains the isotonic environment of the blood. Moreover, serum albumin level is a good indicator of the nutritional index in elderly people. Prothrombin is related to coagulation ability. Fibrinogen is related to hemostasis by helping blood clots to form. In general, with advance of age, the ability to synthesize proteins, especially albumin, and metabolic function of the liver decline. Furthermore, the volume and blood flow of the liver in elderly people are decreased[26].

Meanwhile, the liver is a characteristic organ that is able to regenerate itself after hepatic resection[27]. It is known that after hepatic resection, the remaining liver expands in volume to compensate for lost tissues. The volumes of the liver after remnant liver regeneration are not different in elderly and young people. However, findings after surgical resection have revealed that the effect of aging on the liver is delayed and reduced proliferation immediately after loss of liver mass[28]. The livers in living-related older donors do not regenerate as quickly as those in younger donors[29]. In an animal experiment, it was found that synthesis of DNA isolated from regenerating livers of aged rats was reduced and delayed compared with that of DNA from young rats[30].

An early study demonstrated that major hepatectomy for elderly patients with primary liver cancer resulted in a high mortality rate (23%). The main cause of death was hepatic insufficiency. It was reported that cirrhosis led to an unacceptable mortality rate of 44% after hepatic resection of 5 or more segments of the liver[31]. The loss of regenerative capacity of old livers may cause serious problems in recovery after major hepatectomy in elderly patients. However, a recent study showed that mortality rate in elderly patients (70 years of age or more) who underwent major hepatectomy was 7.9%, which was not so different from that (5.4%) in younger patients, although most of the patients enrolled in that study had metastatic cancer[32].

**COMORBID DISEASE**

In general, the proportion of comorbid disease such as cardiovascular, cerebrovascular, pulmonary or renal diseases, hypertension, and diabetes mellitus is higher in elderly patients than in younger patients[10,11,18,19,21,23,33-35]. The proportion of comorbid disease in elderly patients is twofold that in younger patients. More than 80% of cancer patients over 65 years of age have at least one comorbid disease requiring treatment[36].

Nanashima *et al*[7] demonstrated that preoperative comorbidity significantly increased with age in HCC patients who underwent hepatectomy. Huang *et al*[33] reported that most of the comorbidities in elderly HCC patients had been well-controlled before hepatectomy, whereas elderly patients presented a significantly higher frequency of preoperative comorbidities than that in younger patients. Especially for elderly patients, it is necessary to assess the comorbid disease and to consider the balance with treatment effect of hepatectomy and the risk of morbidity after hepatectomy. The presence of comorbid diseases has been shown to be an important risk factor of mortality or morbidity after surgical procedures in various surgical risk models mentioned below [36-39].

Diabetes mellitus is also a frequent comorbid disease in elderly patients. Diabetes mellitus increases the risk for development of HCC[38]. Moreover, diabetes mellitus in HCC patients after hepatectomy is related to a higher rate of postoperative morbidity and worse postoperative survival rate[39]. A recent report warns liver surgeons against shocking results of major hepatectomy for patients with metabolic disorders. Postoperative mortality in patients undergoing right hepatectomy with two or more metabolic disorders including diabetes mellitus, hypertension, dyslipidemia and obesity reached 30%. Moreover, the mortality rate in patients with three or more metabolic disorders reached 54%[37]. Although it is essential to control metabolic disorders medically before hepatectomy, the indication of major hepatectomy for patients with serious metabolic disorders should be reconsidered.

**GENERAL SURGICAL RISK MODEL IN HEPATECTOMY**

The treatment strategy for HCC patients is decided mainly according to their physiological status, hepatic functional reserve and tumor stage. Hepatectomy for HCC patients, especially for elderly HCC patients, is still a risky procedure with significant morbidity and mortality. The prevalence of HCC in a series of elderly patients undergoing hepatectomy ranged from 22.7% to 46.7%[40,41]. Patient with poor physiological status are not candidates for invasive procedures including hepatectomy. Careful patient selection is the key to achieving acceptable outcomes after hepatectomy (Table 1).

According to the guidelines of clinical practice for HCC in Japan[42], treatment strategies should be decided by considering both the tumor factor and hepatic functional reserve. There is no restriction for age or PS in the guidelines. Barcelona-Clinic Liver Cancer (BCLC) staging classification and treatment schedule classifies HCC patients by variables related to tumor stage, liver functional status, physical status, and cancer-related symptoms. With regard to physical status, hepatectomy is indicative for a patient with PS 0, 1 or a small part of 2.

Evidence-based, patient-specific risk prediction is valuable in the decision-making process. Although age by itself is not a strong risk factor of mortality or morbidity, when considering other physiologic factors[43], age may be a proxy for physiological reserve[44, 45] and a surrogate marker for undeclared comorbidity. Thus, we have to determine candidates for hepatectomy with not only consideration of the tumor stage and hepatic functional reserve but also use of physiological assessment tools. The variety of scoring systems for surgical procedures indicates how numerous the variables are that can be analyzed to derive mortality and morbidity rates.

The American Society of Anesthesiologists (ASA) score, which has been widely used, is a useful indicator of morbidity after abdominal surgery in elderly patients[46]. It is incorporated in a number of other scoring systems. The advantages of the ASA score are that it can be simply applied and it is better for risk stratification, while the disadvantages are that it is not designed as an operative risk score and it is not specific and not predictive[47].

 Physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM score)[48], Portsmouth POSSUM (P-POSSUM)[49], Estimation of physiologic ability and surgical stress (E-PASS) score[50, 51] have been reported as measures for surgical audit to evaluate the operative risk objectively by preoperative condition of the patient and surgical stress.

POSSUM and P-POSSUM provide information on predicted risk in terms of morbidity and mortality. Clinical parameters included in the POSSUM/P-POSSUM and E-PASS scoring is shown in Table 1. Both scoring systems consist of physiologic and operative parameters. At present, the predicted mortality rates and morbidity rates from the POSSUM or P-POSSUM scoring system can be easily calculated to enter the appropriate numerical values on the Internet. However, there are some problems in the scoring systems including occurrence of an error due to differences among facilities or ethnic groups and difficulty in examining many parameters.

The E-PASS scoring system was initially developed by Haga *et al*[50] to predict adverse postoperative effects in a study population of approximately 300 patients requiring elective gastrointestinal surgery. This scoring system is composed of a Preoperative Risk Score (PRS), Surgical Stress Score (SSS), and Comprehensive Risk Score (CRS). E-PASS uses coefficients to combine pre-operative factors with operative ones. E-PASS also incorporates age and the ASA score. Haga *et al*[50] reported that the in–hospital mortality and morbidity rates in patients with liver cancer increased as the CRS increased. The E-PASS scoring system requires no special examination compared with the POSSUM and P-POSSUM scoring systems. Estimated mortality rates are obtained from equations including CRS. Age is an important risk factor for these scoring systems as well as cardiovascular disease and diabetes mellitus. PRS in the E-PASS scoring system and the POSSUM morbidity and mortality risk in elderly HCC patients are higher than those in younger HCC patients[20]. However, Banz *et al*[52]. reported that the E-PASS scoring system effectively predicted mortality but not morbidity in hepatectomy for patients with benign or malignant liver tumors. They concluded that the E-PASS scoring system cannot be used in its current form and requires further evaluation and validation to better fit the postoperative predictions specific to liver surgery Nanashima *et al*[7] demonstrated that PRS in the E-PASS system increased with age and was strongly correlated to postoperative systemic complications rate, but not to liver-related complications such as hepatic insufficiency, ascites or plural effusion, and bile leakage, in HCC patients who underwent hepatectomy. Recently, Haga *et al*[53] demonstrated that both E-PASS and P-POSSUM had high discriminatory power for predicting postoperative outcomes even in liver surgery but overpredicted the overall mortality rate by more than twofold. Therefore, they proposed that E-PASS should be refined to make it more suitable for predicting liver surgery outcomes.

The Acute Physiology and Chronic Health Evaluation (APACHE) method for predicting hospital mortality enables accurate estimation of the probability of in-hospital death in patients admitted to the intensive care unit (ICU)[54]. Gagner *et al*[55]reported that the APACHE II score could predict the risk of morbidity and mortality in elective hepatectomy for malignancy. However, the APACHE II method is complex and time-consuming, and raw data are not always easily obtainable, particularly outside the ICU setting.

**RISK ASSESSMENT SPECIFIC FOR ELDERLY PATIENTS UNDERGOING HEPATECTOMY**

There are a few scoring systems, in which age of the patient or physiological status is factored, that are specific to HCC patients for hepatectomy to estimate the risk of in-hospital death after hepatectomy. Recently, Simons and colleagues[2] developed a simple risk scoring system to estimate the risk of in-hospital death after resection of HCC. The five patient characteristics that predict in-hospital mortality after hepatectomy include age group, sex, Charlson comorbidity score group, procedures for HCC, and teaching hospital status. The strongest predictors of in-hospital death were a Charlson score of 3 or more (indicating at least 2 comorbid conditions or those with greater severity) and a more invasive procedure (lobectomy). The total possible score was 22. They graded the patients into 4 groups: low, scores from 0 to 4; low to moderate, scores from 5 to 9; moderate to high, scores from 10 to 14; and high, scores from 15 to 22. The estimated mortality rates in those 4 groups were 1.48%, 3.98%, 10.33% and 28.30%, respectively. The risk score for age of more than 75 years was 3 (Table 2).

A preoperative nomogram using a population-based database in USA to predict perioperative mortality risk after liver resections for malignancy has recently been developed[56]. The risk factors of this nomogram include age, race, gender, liver primary, coagulopathy, renal failure, congestive heart failure, cardiac arrhythmias and other major comorbidities. The nomogram was also validated successfully by a high-volume center and is the only clinical tool that has been externally validated to predict preoperative mortality after liver resections for malignancy[57].

**CHARACTERISTICS OF ELDERLY HCC PATIENTS WHO UNDERWENT HEPATECTOMY**

The characteristic of elderly HCC patients are a higher proportion of females, lower rate of positive hepatitis B surface antigen (HBs-Ag), better liver functional reserve and higher proportion of normal livers[8,58] (Table 3).

Hepatic resection rate for elderly HCC patients ranged from 0% to 14%, while that for younger HCC patients was 12% -28%[8,10,34,58]. Hepatic resection rates for elderly HCC patients were lower than those for younger HCC patients. Very old patients did not frequently receive surgical treatment and they were more likely to receive conservative treatment[8].

A summary of the characteristics of previously reported elderly HCC patients who underwent hepatectomy is shown in Table 3. Similarly to characteristics of all elderly HCC patients, five studies have shown that the proportion of females in elderly HCC patients is higher than that in younger HCC patients[10,18,19,21,59]. Four of those studies were recent studies. The reasons for the higher proportion of females in elderly HCC patients are that the average life expectancy at birth of females is longer than that of males and that the proportion of females is higher than that of males in the elderly population. Moreover, the peak age of occurrence of HCC in females is 5 years older than that in males[60].

Most studies have shown that the rate of positive HBs-Ag was lower in elderly HCC patients than in younger HCC patients[12,14-17,19,21,23,33,35,61]. There are many HBV-related HCC patients in China, and lower HBs-Ag rates in elderly HCC patients have been reported even in China. On the other hand, the rate of positive HCV antibody (HCV-Ab) is higher in elderly HCC patients than in younger HCC patients[9,11-13,17,19,33,35,59].

Most studies have shown that serum albumin levels are not different in elderly HCC patients and younger HCC patients[10-13,17,19,20,25,33,62,63]. Similarly, most studies have shown that the values of indocyanine–green retention rate at 15 min (ICG-R15) are not different in elderly and younger HCC patients[9-11,13,15-17,19,20,24,25,59,62,64], while two studies showed that the values of ICG-R15 in elderly HCC patients with hepatectomy were higher than those in younger HCC patients[21,23]. Hepatic functional reserve in elderly HCC patients was almost the same as that in younger HCC patients. Surgeons therefore have the same treatment policy for evaluating hepatic functional reserve before hepatectomy in elderly patients and younger patients.

Regarding tumor factors, Huang et al. reported that there was a significantly higher frequency of tumor encapsulation in elderly HCC patients than in younger patients[27]. Tumor encapsulation has been reported to be a favorable prognostic factor for HCC[65]. In addition, higher incidence of tumor encapsulation indicates higher differentiation of HCC and less incidence of vascular invasion[12]. It was suggested that a higher frequency of tumor encapsulation might be an indicator of less malignant degree in elderly patients with HCC[27].

**SHORT-TERM OUTCOME OF HEPATECTOMY FOR ELDERLY HCC PATIENTS**

The mortality rate after hepatectomy for elderly HCC patients ranged from 0% to 42.9% (Table 4). However, due to recent advances in the surgical procedure and perioperative management, most recent studies have shown that the mortality rates after hepatectomy in elderly patients and younger patients are not different[14-17,20,21,24,25,33,35,59,61,63,64]. Child-pugh B and C are risk factors of operative death for elderly HCC patients[66]. Regarding major hepatectomy, although the degree of liver regeneration at one month after right lobectomy in elderly patients is not different from that in younger patients, the incidence of hospital death due to hepatic failure after right lobectomy in elderly HCC patients is extremely high[62]. It is possible that remnant liver regeneration immediately after major hepatectomy in elderly patients is impaired[67] (Table 4).

The morbidity rate after hepatectomy for elderly HCC patients ranged from 9% to 51%. Despite the high rate of comorbidity disease in elderly patients as mentioned above, most studies have shown that morbidity rates of elderly patients are not different from those in younger patients. On the other hand, Ferrero et al. reported that postoperative morbidity rate was lower in elderly HCC patients[13]. Moreover, Kondo *et al*[14] reported that the frequency of pneumonia is the only difference in postoperative complications.

Meanwhile, the mortality and morbidity rates after hepatectomy in elderly patients with colorectal liver metastasis (CLM) are from 0 to 8% and from 14.2% to 52.5%, respectively. Those rates in elderly patients with CLM are not different from those in elderly patients with HCC[68].

**LONG-TERM OUTCOME OF HEPATECTOMY FOR ELDERLY HCC PATIENTS**

Overall survival rates after hepatectomy in elderly HCC patients at 5 years ranged from 26% to 75.9%, whereas those in younger HCC patients ranged from 31.4%% to 68%[9-13,15,16,19,20,23-25,33,34,59,61,64]. Most reports demonstrated that overall survival rates after hepatectomy at 5 years are not different in elderly and younger patients[9-13,15,16,19,20,23-25,34,59,61,63,64]. Only one study showed better overall survival rates after hepatectomy at 5 years in elderly patients[33]. In that study, the overall 5-year survival rates after hepatectomy were 43.2% in the elderly group and 31.4% in the younger group, whereas 5-year disease-free survival rate in the elderly group was not significantly different from that in the younger group. Thus, it was suggested that elderly patients with HCC possibly had longer tumor-bearing survival than that of younger patients because HCC in the elderly patients was less advanced and less aggressive[27](Table 4).

Since the majority of elderly patients have various comorbidities, deaths unrelated to HCC may have affected the survival rate in the elderly group. However, long-term results for elderly HCC patients who underwent hepatectomy were almost the same as those for younger patients. One possible explanation is that elderly patients who undergo hepatectomy might be strictly selected before referring to hospitals because hepatectomy is a more invasive procedure than other gastrointestinal surgeries.

Postoperative recurrence of HCC is the most important factor affecting survival of patients who have undergone radical resection. Repeated hepatectomy has been suggested to be the most effective treatment for recurrent HCC[69]. Even for elderly patients with recurrent HCC, repeated hepatectomy has also been recommended to achieve better survival if the tumors are resectable and hepatic functional reserve is preserved[11]. Tsujita *et al*[17] reported that the criteria of initial therapy for recurrent HCC are identical to those of initial treatment for primary HCC even in elderly patients.

Meanwhile, overall survival rates at 5 years in elderly patients with CLM are 16% to 38%. The outcomes for elderly patients undergoing hepatectomy for HCC are better than those for elderly patients undergoing hepatectomy for CLM[68].

**CONCLUSION**

The average life expectancy at birth and the number of elderly HCC patients have been increasing worldwide. Thus, the necessity of invasive treatments including hepatectomy for elderly patients has been increasing. Hepatectomy can now be performed safely for strictly selected elderly patients. With strict preoperative evaluation, both short-term and long-term results after hepatectomy for elderly HCC patients are almost the same as those for younger patients. Considering physiological characteristics and high prevalence of comorbid disease in elderly patients, it is important to assess patients more meticulously and to plan an elective operation in detail for elderly patient scheduled to undergo major hepatectomy.

**REFERENCES**

1 **Jemal A**, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; **61**: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]

2 **Simons JP**, Ng SC, Hill JS, Shah SA, Zhou Z, Tseng JF. In-hospital mortality from liver resection for hepatocellular carcinoma: a simple risk score. *Cancer* 2010; **116**: 1733-1738 [PMID: 20143433 DOI: 10.1002/cncr.24904]

3 **Health and Welfare Statistics Association.** Life expectancy. *J Health Welfare Stat* 2004; **51**: 67-68

4 **Taura N**, Hamasaki K, Nakao K, Ichikawa T, Nishimura D, Goto T, Fukuta M, Kawashimo H, Miyaaki H, Fujimoto M, Kusumoto K, Motoyoshi Y, Shibata H, Inokuchi K, Eguchi K. Aging of patients with hepatitis C virus-associated hepatocellular carcinoma: long-term trends in Japan. *Oncol Rep* 2006; **16**: 837-843 [PMID: 16969503]

5 **Ohishi W**, Kitamoto M, Aikata H, Kamada K, Kawakami Y, Ishihara H, Kamiyasu M, Nakanishi T, Tazuma S, Chayama K. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. *Scand J Gastroenterol* 2003; **38**: 894-900 [PMID: 12940445]

6 **Ikai I**, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, Takayasu K, Hayashi N, Makuuchi M, Matsuyama Y, Monden M. Report of the 18th follow-up survey of primary liver cancer in Japan. *Hepatology Research* 2010; **40**: 1043-1059 [DOI: 10.1111/jgh.12350]

7 **Nanashima A**, Abo T, Nonaka T, Fukuoka H, Hidaka S, Takeshita H, Ichikawa T, Sawai T, Yasutake T, Nakao K, Nagayasu T. Prognosis of patients with hepatocellular carcinoma after hepatic resection: are elderly patients suitable for surgery? *J Surg Oncol* 2011; **104**: 284-291 [PMID: 21462192 DOI: 10.1002/jso.21932]

8 **Tsukioka G**, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Abe T, Toyoda M, Katakai K, Kojima A, Yamazaki Y, Otsuka T, Matsuzaki Y, Makita F, Kanda D, Horiuchi K, Hamada T, Kaneko M, Suzuki H, Mori M. Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival. *World J Gastroenterol* 2006; **12**: 48-53 [PMID: 16440416]

9 **Takenaka K**, Shimada M, Higashi H, Adachi E, Nishizaki T, Yanaga K, Matsumata T, Ikeda T, Sugimachi K. Liver resection for hepatocellular carcinoma in the elderly. *Arch Surg* 1994; **129**: 846-850 [PMID: 8048856]

10 **Poon RT**, Fan ST, Lo CM, Liu CL, Ngan H, Ng IO, Wong J. Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. *Am J Gastroenterol* 1999; **94**: 2460-2466 [PMID: 10484009 DOI: 10.1111/j.1572-0241.1999.01376.x]

11 **Hanazaki K**, Kajikawa S, Shimozawa N, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J. Hepatic resection for hepatocellular carcinoma in the elderly. *J Am Coll Surg* 2001; **192**: 38-46 [PMID: 11192921]

12 **Yeh CN**, Lee WC, Jeng LB, Chen MF. Hepatic resection for hepatocellular carcinoma in elderly patients. *Hepatogastroenterology* 2004; **51**: 219-223 [PMID: 15011868]

13 **Ferrero A**, Viganò L, Polastri R, Ribero D, Lo Tesoriere R, Muratore A, Capussotti L. Hepatectomy as treatment of choice for hepatocellular carcinoma in elderly cirrhotic patients. *World J Surg* 2005; **29**: 1101-1105 [PMID: 16088422 DOI: 10.1007/s00268-005-7768-2]

14 **Kondo K**, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J. Hepatic resection is justified for elderly patients with hepatocellular carcinoma. *World J Surg* 2008; **32**: 2223-2229 [PMID: 18642042 DOI: 10.1007/s00268-008-9688-4]

15 **Kaibori M**, Matsui K, Ishizaki M, Saito T, Kitade H, Matsui Y, Kwon AH. Hepatic resection for hepatocellular carcinoma in the elderly. *J Surg Oncol* 2009; **99**: 154-160 [PMID: 19123236 DOI: 10.1002/jso.21221]

16 **Oishi K**, Itamoto T, Kobayashi T, Oshita A, Amano H, Ohdan H, Tashiro H, Asahara T. Hepatectomy for hepatocellular carcinoma in elderly patients aged 75 years or more. *J Gastrointest Surg* 2009; **13**: 695-701 [PMID: 19050982 DOI: 10.1007/s11605-008-0758-6]

17 **Tsujita E**, Utsunomiya T, Ohta M, Tagawa T, Matsuyama A, Okazaki J, Yamamoto M, Tsutsui S, Ishida T. Outcome of repeat hepatectomy in patients with hepatocellular carcinoma aged 75 years and older. *Surgery* 2010; **147**: 696-703 [PMID: 20015526 DOI: 10.1016/j.surg.2009.10.054]

18 **Fujii H**, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y, Nishida K, Ohkawara Y, Yamaguchi K, Minami M, Okanoue T. Factors associated with the overall survival of elderly patients with hepatocellular carcinoma. *World J Gastroenterol* 2012; **18**: 1926-1932 [PMID: 22563173 DOI: 10.3748/wjg.v18.i16.1926]

19 **Nishikawa H**, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Surgical resection for hepatocellular carcinoma: clinical outcomes and safety in elderly patients. *Eur J Gastroenterol Hepatol* 2013; **25**: 912-919 [PMID: 23470356 DOI: 10.1097/MEG.0b013e32835fa668]

20 **Ide T**, Miyoshi A, Kitahara K, Noshiro H. Prediction of postoperative complications in elderly patients with hepatocellular carcinoma. *J Surg Res* 2013; **185**: 614-619 [PMID: 23932657 DOI: 10.1016/j.jss.2013.07.016]

21 **Ueno M**, Hayami S, Tani M, Kawai M, Hirono S, Yamaue H. Recent trends in hepatectomy for elderly patients with hepatocellular carcinoma. *Surg Today* 2013 [PMID: 24091862 DOI: 10.1007/s00595-013-0739-6]

22 **Caratozzolo E**, Massani M, Recordare A, Bonariol L, Baldessin M, Bassi N. Liver resection in elderly: comparative study between younger and older than 70 years patients. Outcomes and implications for therapy. *G Chir* 2007; **28**: 419-424 [PMID: 18035008]

23 **Wu CC**, Chen JT, Ho WL, Yeh DC, Tang JS, Liu TJ, P'eng FK. Liver resection for hepatocellular carcinoma in octogenarians. *Surgery* 1999; **125**: 332-338 [PMID: 10076619]

24 **Yamada S**, Shimada M, Miyake H, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Iwahashi S, Saito Y. Outcome of hepatectomy in super-elderly patients with hepatocellular carcinoma. *Hepatol Res* 2012; **42**: 454-458 [PMID: 22295877 DOI: 10.1111/j.1872-034X.2011.00952.x]

25 **Tsujita E**, Utsunomiya T, Yamashita Y, Ohta M, Tagawa T, Matsuyama A, Okazaki J, Yamamoto M, Tsutsui S, Ishida T. Outcome of hepatectomy in hepatocellular carcinoma patients aged 80 years and older. *Hepatogastroenterology* 2012; **59**: 1553-1555 [PMID: 22683972 DOI: 10.5754/hge09485]

26 **Jansen PL**. Liver disease in the elderly. *Best Pract Res Clin Gastroenterol* 2002; **16**: 149-158 [PMID: 11977934 DOI: 10.1053/bega.2002.0271]

27 **Michalopoulos GK**. Liver regeneration. *J Cell Physiol* 2007; **213**: 286-300 [PMID: 17559071 DOI: 10.1002/jcp.21172]

28 **Timchenko NA**. Aging and liver regeneration. *Trends Endocrinol Metab* 2009; **20**: 171-176 [PMID: 19359195 DOI: 10.1016/j.tem.2009.01.005]

29 **Taki-Eldin A**, Zhou L, Xie HY, Zheng SS. Liver regeneration after liver transplantation. *Eur Surg Res* 2012; **48**: 139-153 [PMID: 22572792 DOI: 10.1159/000337865]

30 **Taguchi T**, Fukuda M, Ohashi M. Differences in DNA synthesis in vitro using isolated nuclei from regenerating livers of young and aged rats. *Mech Ageing Dev* 2001; **122**: 141-155 [PMID: 11166354]

31 **Koperna T**, Kisser M, Schulz F. Hepatic resection in the elderly. *World J Surg* 1998; **22**: 406-412 [PMID: 9523524]

32 **Menon KV**, Al-Mukhtar A, Aldouri A, Prasad RK, Lodge PA, Toogood GJ. Outcomes after major hepatectomy in elderly patients. *J Am Coll Surg* 2006; **203**: 677-683 [PMID: 17084329 DOI: 10.1016/j.jamcollsurg.2006.07.025]

33 **Huang J**, Li BK, Chen GH, Li JQ, Zhang YQ, Li GH, Yuan YF. Long-term outcomes and prognostic factors of elderly patients with hepatocellular carcinoma undergoing hepatectomy. *J Gastrointest Surg* 2009; **13**: 1627-1635 [PMID: 19506976 DOI: 10.1007/s11605-009-0933-4]

34 **Mirici-Cappa F**, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, Maraldi F, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M, Trevisani F. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. *Gut* 2010; **59**: 387-396 [PMID: 20207642 DOI: 10.1136/gut.2009.194217]

35 **Portolani N**, Baiocchi GL, Coniglio A, Tiberio GA, Prestini K, Gheza F, Benetti A, Maria Giulini S. Limited liver resection: a good indication for the treatment of hepatocellular carcinoma in elderly patients. *Jpn J Clin Oncol* 2011; **41**: 1358-1365 [PMID: 22039578 DOI: 10.1093/jjco/hyr154]

36 **Yancik R**, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. *J Clin Oncol* 2001; **19**: 1147-1151 [PMID: 11181680]

37 **Zarzavadjian Le Bian A**, Costi R, Constantinides V, Smadja C. Metabolic disorders, non-alcoholic fatty liver disease and major liver resection: an underestimated perioperative risk. *J Gastrointest Surg* 2012; **16**: 2247-2255 [PMID: 23054903 DOI: 10.1007/s11605-012-2044-x]

38 **El-Serag HB**, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* 2004; **126**: 460-468 [PMID: 14762783]

39 **Ikeda Y**, Shimada M, Hasegawa H, Gion T, Kajiyama K, Shirabe K, Yanaga K, Takenaka K, Sugimachi K. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. *Hepatology* 1998; **27**: 1567-1571 [PMID: 9620328 DOI: 10.1002/hep.510270615]

40 **Aldrighetti L**, Arru M, Catena M, Finazzi R, Ferla G. Liver resections in over-75-year-old patients: surgical hazard or current practice? *J Surg Oncol* 2006; **93**: 186-193 [PMID: 16482597 DOI: 10.1002/jso.20342]

41 **Reddy SK**, Barbas AS, Turley RS, Gamblin TC, Geller DA, Marsh JW, Tsung A, Clary BM, Lagoo-Deenadayalan S. Major liver resection in elderly patients: a multi-institutional analysis. *J Am Coll Surg* 2011; **212**: 787-795 [PMID: 21435922 DOI: 10.1016/j.jamcollsurg.2010.12.048]

42 **Makuuchi M**, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, Yamaoka Y. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. *Hepatol Res* 2008; **38**: 37-51 [PMID: 18039202 DOI: 10.1111/j.1872-034X.2007.00216.x]

43 **Makuuchi M**, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S. Surgery for small liver cancers. *Semin Surg Oncol* 1993; **9**: 298-304 [PMID: 8210909]

44 **Goldhill DR**. Preventing surgical deaths: critical care and intensive care outreach services in the postoperative period. *Br J Anaesth* 2005; **95**: 88-94 [PMID: 15486009 DOI: 10.1093/bja/aeh281]

45 **Cucchetti A**, Ercolani G, Cescon M, Ravaioli M, Zanello M, Del Gaudio M, Lauro A, Vivarelli M, Grazi GL, Pinna AD. Recovery from liver failure after hepatectomy for hepatocellular carcinoma in cirrhosis: meaning of the model for end-stage liver disease. *J Am Coll Surg* 2006; **203**: 670-676 [PMID: 17084328 DOI: 10.1016/j.jamcollsurg.2006.06.018]

46 **Hall JC**, Hall JL. ASA status and age predict adverse events after abdominal surgery. *J Qual Clin Pract* 1996; **16**: 103-108 [PMID: 8794400]

47 **Chandra A**, Mangam S, Marzouk D. A review of risk scoring systems utilised in patients undergoing gastrointestinal surgery. *J Gastrointest Surg* 2009; **13**: 1529-1538 [PMID: 19319612 DOI: 10.1007/s11605-009-0857-z]

48 **Copeland GP**, Jones D, Walters M. POSSUM: a scoring system for surgical audit. *Br J Surg* 1991; **78**: 355-360 [PMID: 2021856]

49 **Prytherch DR**, Whiteley MS, Higgins B, Weaver PC, Prout WG, Powell SJ. POSSUM and Portsmouth POSSUM for predicting mortality. Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity. *Br J Surg* 1998; **85**: 1217-1220 [PMID: 9752863 DOI: 10.1046/j.1365-2168.1998.00840.x]

50 **Haga Y**, Wada Y, Takeuchi H, Kimura O, Furuya T, Sameshima H, Ishikawa M. Estimation of physiologic ability and surgical stress (E-PASS) for a surgical audit in elective digestive surgery. *Surgery* 2004; **135**: 586-594 [PMID: 15179364 DOI: 10.1016/j.surg.2003.11.012]

51 **Haga Y**, Ikei S, Ogawa M. Estimation of Physiologic Ability and Surgical Stress (E-PASS) as a new prediction scoring system for postoperative morbidity and mortality following elective gastrointestinal surgery. *Surg Today* 1999; **29**: 219-225 [PMID: 10192731]

52 **Banz VM**, Studer P, Inderbitzin D, Candinas D. Validation of the estimation of physiologic ability and surgical stress (E-PASS) score in liver surgery. *World J Surg* 2009; **33**: 1259-1265 [PMID: 19290570 DOI: 10.1007/s00268-009-9989-2]

53 **Haga Y**, Ikejiri K, Takeuchi H, Ikenaga M, Wada Y. Value of general surgical risk models for predicting postoperative liver failure and mortality following liver surgery. *J Surg Oncol* 2012; **106**: 898-904 [PMID: 22605669 DOI: 10.1002/jso.23160]

54 **Zimmerman JE**, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. *Crit Care Med* 2006; **34**: 1297-1310 [PMID: 16540951 DOI: 10.1097/01.CCM.0000215112.84523.F0]

55 **Gagner M**, Franco D, Vons C, Smadja C, Rossi RL, Braasch JW. Analysis of morbidity and mortality rates in right hepatectomy with the preoperative APACHE II score. *Surgery* 1991; **110**: 487-492 [PMID: 1887371]

56 **Dhir M**, Smith LM, Ullrich F, Leiphrakpam PD, Ly QP, Sasson AR, Are C. Pre-operative nomogram to predict risk of peri-operative mortality following liver resections for malignancy. *J Gastrointest Surg* 2010; **14**: 1770-1781 [PMID: 20824363 DOI: 10.1007/s11605-010-1352-2]

57 **Greco E**, Nanji S, Bromberg IL, Shah S, Wei AC, Moulton CA, Greig PD, Gallinger S, Cleary SP. Predictors of peri-opertative morbidity and liver dysfunction after hepatic resection in patients with chronic liver disease. *HPB (Oxford)* 2011; **13**: 559-565 [PMID: 21762299 DOI: 10.1111/j.1477-2574.2011.00329.x]

58 **Honda T**, Miyaaki H, Ichikawa T, Taura N, Miuma S, Shibata H, Isomoto H, Takeshima F, Nakao K. Clinical characteristics of hepatocellular carcinoma in elderly patients. *Oncol Lett* 2011; **2**: 851-854 [PMID: 22866139 DOI: 10.3892/ol.2011.359]

59 **Hirokawa F**, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Takeshita A, Shibayama Y, Uchiyama K. Surgical outcomes and clinical characteristics of elderly patients undergoing curative hepatectomy for hepatocellular carcinoma. *J Gastrointest Surg* 2013; **17**: 1929-1937 [PMID: 24002762 DOI: 10.1007/s11605-013-2324-0]

60 **El-Serag HB**, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007; **132**: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]

61 **Zhou L**, Rui JA, Wang SB, Chen SG, Qu Q, Chi TY, Wei X, Han K, Zhang N, Zhao HT. Clinicopathological features, post-surgical survival and prognostic indicators of elderly patients with hepatocellular carcinoma. *Eur J Surg Oncol* 2006; **32**: 767-772 [PMID: 16725304 DOI: 10.1016/j.ejso.2006.03.050]

62 **Yamamoto K**, Takenaka K, Matsumata T, Shimada M, Itasaka H, Shirabe K, Sugimachi K. Right hepatic lobectomy in elderly patients with hepatocellular carcinoma. *Hepatogastroenterology* 1997; **44**: 514-518 [PMID: 9164528]

63 **Wang WL**, Zhu Y, Cheng JW, Li MX, Xia JM, Hao J, Yu L, Lv Y, Wu Z, Wang B. Major hepatectomy is safe for hepatocellular carcinoma in elderly patients with cirrhosis. *Eur J Gastroenterol Hepatol* 2014; **26**: 444-451 [PMID: 24463566 DOI: 10.1097/meg.0000000000000046]

64 **Taniai N**, Yoshida H, Yoshioka M, Kawano Y, Uchida E. Surgical outcomes and prognostic factors in elderly patients (75 years or older) with hepatocellular carcinoma who underwent hepatectomy. *J Nippon Med Sch* 2013; **80**: 426-432 [PMID: 24419713]

65 **Nagao T**, Inoue S, Goto S, Mizuta T, Omori Y, Kawano N, Morioka Y. Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis. *Ann Surg* 1987; **205**: 33-40 [PMID: 3026259]

66 **Nagasue N**, Chang YC, Takemoto Y, Taniura H, Kohno H, Nakamura T. Liver resection in the aged (seventy years or older) with hepatocellular carcinoma. *Surgery* 1993; **113**: 148-154 [PMID: 8381563]

67 **Shirabe K**, Motomura T, Takeishi K, Morita K, Kayashima H, Taketomi A, Ikegami T, Soejima Y, Yoshizumi T, Maehara Y. Human early liver regeneration after hepatectomy in patients with hepatocellular carcinoma: special reference to age. *Scand J Surg* 2013; **102**: 101-105 [PMID: 23820685 DOI: 10.1177/1457496913482250]

68 **Zhou Y**, Zhang X, Zhang Z, Liu X, Wu L, Li Y, Li B. Hepatectomy in elderly patients: does age matter? *World J Surg* 2013; **37**: 2899-2910 [PMID: 23959339 DOI: 10.1007/s00268-013-2184-5]

69 **Itamoto T**, Nakahara H, Amano H, Kohashi T, Ohdan H, Tashiro H, Asahara T. Repeat hepatectomy for recurrent hepatocellular carcinoma. *Surgery* 2007; **141**: 589-597 [PMID: 17462458 DOI: 10.1016/j.surg.2006.12.014]

**P-Reviewer:** Abdul-Wahed NM, De Nardi P, Zezos P **S-Editor:** Ma N **L-Editor: E-Editor:**

**Table 1 General surgical risk model in hepatectomy**

|  |  |  |  |
| --- | --- | --- | --- |
| 　 | **POSSUM/pPOSSUM** | **E-PASS** | **APACHE II score** |
| **Physiological parameters** |  |  |
|  | Age | Age | Age |
|  | Cardiac history | Severe heart disease | Chornic health point |
|  | Respiratory history | Severe pulmonary disease | Temperature |
|  | Blood pressure | Diabetes mellitus | Blood pressure |
|  | Pulse rate | Performance status | Heart rate |
|  | Glasgow Coma scale | ASA score | Respiratory rate |
|  | Hemoglobin level |  | Oxygenation |
|  | White cell count |  | Arterial pH |
|  | Urea concentration |  | Serum sodium |
|  | Serum sodium level |  | Serum potassium |
|  | Serum potassium level |  | Serum creatinine |
|  | Electrocardiography |  | Hematocrit |
|  |  |  | White blood cell count |
|  |  |  | Glasgow Coma Score |
| **Operative paramerters** | 　 | 　 |
|  | Operative sverity | Blood loss/Body weight |  |
|  | Multiple procedures | Operation time |  |
|  | Total blood loss | Extent of skin incision |  |
|  | Peritoneal soiling |  |  |
|  | Presence of malignancy |  |  |
| 　 | Mode of surgery | 　 | 　 |

**Table 2 Risk assessment specific for elderly patients undergoing hepatectomy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Simple Risk Score** |  | **Nomogram** |  |
| **Physiological parameters** | **Point**  |  |  | **Point**  |
|  | Age |  |  | Age |  |  |
|  |  | ≤ 55 | 0 |  | 18-54 | 0 |
|  |  | 55-75 | 1 |  | 55-70 | 25 |
|  |  | >75 | 4 |  | ≥ 70 | 54 |
|  | Sex |  |  | Sex |  |  |
|  |  | Women | 0 |  | Women | 0 |
|  |  | Men | 1 |  | Men | 19 |
|  | Hospital type |  | Race |  |  |
|  |  | Teaching | 0 |  | White | 0 |
|  |  | Nonteaching | 3 |  | Non white | 21 |
|  | Charlson comorbidity score |  | Admission type |  |
|  |  | 0 | 0 |  | Elective | 8 |
|  |  | 1 | 3 |  | Urgent/Emergent | 32 |
|  |  | 2 | 4 | Liver primary |  |
|  |  | ≥ 3 | 8 |  | No | 0 |
|  |  |  |  |  | Yes | 25 |
|  |  |  |  | Hypertension |  |
|  |  |  |  |  | Yes | 0 |
|  |  |  |  |  | No | 61 |
|  |  |  |  | Coagulopathy |  |
|  |  |  |  |  | No | 0 |
|  |  |  |  |  | Yes | 100 |
|  |  |  |  | Renal failure |  |
|  |  |  |  |  | No | 0 |
|  |  |  |  |  | Yes | 87 |
|  |  |  |  | Congestive heart failure |  |
|  |  |  |  |  | No | 0 |
|  |  |  |  |  | Yes | 49 |
|  |  |  |  | Cardiac arrhythmias |  |
|  |  |  |  |  | No | 0 |
|  |  |  |  |  | Yes | 47 |
|  |  |  |  | Liver disease |  |
|  |  |  |  |  | No | 0 |
|  |  |  |  |  | Yes | 41 |
|  |  |  |  | Fluid and electrolyte disorders |  |
|  |  |  |  |  | No | 0 |
|  |  |  |  |  | Yes | 52 |
|  |  |  |  | COPD |  |  |
|  |  |  |  |  | No | 0 |
|  |  |  |  |  | Yes | 17 |
|  |  |  |  | Other neurological disorders |  |
|  |  |  |  |  | No | 0 |
| 　 | 　 | 　 | 　 | 　 | Yes | 95 |
| Operative paramerters | 　 | 　 | 　 | 　 |
|  | Procedure type | 　 | Procedure type | 　 |
|  |  | RFA/enucleation | 0 |  | Wedge resection | 0 |
|  |  | Wedge resection | 2 |  | Lobectomy | 27 |
| 　 | 　 | Lobectomy | 6 | 　 | 　 | 　 |

**Table 3 Characteristics of elderly hepatocellular carcinoma patients**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Country** | **Age** | **Number of patients** |  | **Sex (male) (%)** |  | **HBV (%)** |  | **HCV (%)** |  | **Child-pugh(B) (%)** |  | **Alb (g/dl)** |  | ICG-R15(%) |
|  |  |  |  | **Y** | **E** |  | **Y** | **E** |  | **Y** | **E** |  | **Y** | **E** |  | **Y** | **E** |  | **Y** | **E** | 　 | Y | E |
| Takenaka *et al*[9] | 1994 | Japan | 70 | 229 | 39 |  | 81 | 69 |  | 18 | 5 |  | 59 | 881 |  | 24 | 13 |  | N/A | N/A |  | 17.4 | 18.7 |
| Yamamoto *et al*[62] | 1997 | Japan | 70 | 40 | 7 |  | 87.5 | 71.4 |  | 10 | 29 |  | 77 | 71 |  | N/A | N/A |  | 3.9 | 4 |  | 13.6 | 11.2 |
| Poon *et al*[10] | 1999 | China | 70 | 299 | 31 |  | 86 | 67.71 |  | 85.9 | 51.6 |  | N/A | N/A |  | 4.7 | 3.2 |  | 4.1 | 4.1 |  | 12.6 | 14 |
| Wu *et al*[23] | 1999 | Taiwan | 80 | 239 | 21 |  | 79.5 | 90.5 |  | 58.5 | 28.61 |  | N/A | N/A |  | 18.8 | 23.8 |  | N/A | N/A |  | 14.2 | 17.7\* |
| Hanazaki *et al*[11] | 2001 | Japan | 70 | 283 | 103 |  | 78.4 | 68.9 |  | 23.7 | 18.4 |  | 40.7 | 55.41 |  | 20.1 | 26.2 |  | 3.7 | 3.7 |  | 21 | 21 |
| Yeh *et al*[12] | 2004 | Taiwan | 70 | 398 | 34 |  | 77.9 | 79.4 |  | 74 | 25.81 |  | 31.8 | 63.21 |  | 23.6 | 33.3 |  | 3.8 | 3.6 |  | 13.3 | 22.6 |
| Ferrero *et al*[13] | 2005 | Italy | 70 | 177 | 64 |  | 81.9 | 73.4 |  | 21.4 | 10.9 |  | 38.9 | 60.91 |  | 22 | 15.6 |  | 3.7 | 3.6 |  | 7.2 | 9.3 |
| Zhou *et al*[61] | 2006 | China | 65 | 125 | 54 |  | 85.6 | 88.9 |  | 84.8 | 59.31 |  | N/A | N/A |  | 4.8 | 14.8\* |  | N/A | N/A |  | N/A | N/A |
| Kondo *et al*[14] | 2008 | Japan | 70 | 210 | 109 |  | 75.7 | 72.4 |  | 41 | 11.91 |  | 45.7 | 54.1 |  | 6.1 | 9.2 |  | N/A | N/A |  | N/A | N/A |
| Kaibori *et al*[15] | 2009 | Japan | 70 | 333 | 155 |  | 80.7 | 76.8 |  | 20.1 | 9.71 |  | 693 | 71.6 |  | 9.3 | 10.3 |  | 3.6 | 3.7\* |  | 18.7 | 19.8 |
| Oishi *et al*[16] | 2009 | Japan | 75 | 502 | 64 |  | 76 | 75 |  | 24 | 21 |  | 66 | 70 |  | 15 | 8 |  | 3.8 | 3.7 |  | 17.7 | 18.7 |
| Huang *et al*[33] | 2009 | China | 70 | 268 | 67 |  | 82.8 | 86.6 |  | 88.8 | 65.71 |  | 1.1 | 7.51 |  | 4.1 | 6 |  | 4.1 | 4 |  | N/A | N/A |
| Mirici-Cappa *et al*[34] | 2010 | Italy | 70 | 142 | 43 |  | 81.7 | 74.4 |  | 15 | 7.1 |  | 47.1 | 57.1 |  | 31.3 | 27.4 |  | N/A | N/A |  | N/A | N/A |
| Tsujita *et al*[17] | 2010 | Japan | 75 | 77 | 23 |  | 67.5 | 73.9 |  | 22 | 0\* |  | 65 | 911 |  | 4 | 0 |  | 4 | 4 |  | 18 | 19 |
| Portolani *et al*[35] | 2011 | Italy | 70 | 276 | 175 |  | 82.2 | 72 |  | 30.8 | 17.1\* |  | 31.9 | 45.11 |  | 8.3 | 6.9 |  | N/A | N/A |  | N/A | N/A |
| Yamada *et al*[24] | 2012 | Japan | 80 | 267 | 11 |  | 77 | 55 |  | 27 | 36 |  | 58 | 56 |  | 8 | 22 |  | 3.7 | 3.3\* |  | 17.6 | 19.4 |
| Tsujita *et al*[25] | 2012 | Japan | 80 | 385 | 23 |  | 65.7 | 65.2 |  | 23.1 | 8.7 |  | 70.6 | 87 |  | 31.7 | 21.7 |  | 3.9 | 4 |  | 17 | 16.5 |
| Nishikawa *et al*[19] | 2013 | Japan | 75 | 206 | 92 |  | 78.1 | 66.31 |  | 17.5 | 4.3\* |  | 56.3 | 66.31 |  | 3.9 | 2.2 |  | 4 | 3.8 |  | 13.9 | 14.6 |
| Hirokawa *et al*[59] | 2013 | Japan | 70 | 120 | 100 |  | 82 | 691 |  | N/A | N/A |  | 50 | 681 |  | 18 | 12 |  | N/A | N/A |  | 14.3 | 15.1 |
| Ide *et al*[20] | 2013 | Japan | 75 | 192 | 64 |  | 82 | 67 |  | 22 | 13 |  | 65 | 69 |  | 13 | 11 |  | 3.9 | 3.9 |  | 15.7 | 19.1 |
| Ueno *et al*[21] | 2013 | Japan | 75 | 186 | 66 |  | 81 | 65\* |  | 20 | 2\* |  | 55 | 56 |  | 9 | 9 |  | 4 | 3.9\* |  | 13 | 14\* |
| Taniai *et al*[64] | 2013 | Japan | 75 | 353 | 63 |  | 77 | 62 |  | N/A | N/A |  | N/A | N/A |  | 24 | 11 |  | N/A | N/A |  | 19.1 | 15 |
| Wang *et al*[63] | 2014 | China | 70 | 152 | 56 | 　 | 79 | 71 | 　 | 98.7 | 96.5 | 　 | 1.3 | 3.6 | 　 | 20 | 14 | 　 | 3.9 | 3.9 | 　 | N/A | N/A |

1Represents significant difference. Y: Younger patients; E: Elderly patients; Alb: Albumin, ICG: Indocyanine–green retention rate at 15 min. HCV: Hepatitis C virus; HBV: Hepatitis B virus; N/A: Not available.

**Table 4 Outcome of hepatectomy for elderly hepatocellular carcinomapatients**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Country** | **age** | **Number of patients** |  | **Mortality rate (%)** |  | **Morbidity rate (%)** |  | **OS at 5 years (%)** |
|  |  |  |  | **Y** | **E** |  | **Y** | **E** |  | **Y** | **E** |  | **Y** | **E** |
| Takenaka *et al*[9] | 1994 | Japan | 70 | 229 | 39 |  | 1 | 5 |  | 50 | 51 |  | 51.6 | 75.9 |
| Yamamoto *et al*[62] | 1997 | Japan | 70 | 40 | 7 |  | 5 | 42.9\* |  | N/A | N/A |  | N/A | N/A |
| Poon *et al*[10] | 1999 | China | 70 | 299 | 31 |  | 6 | 10 |  | 40 | 48 |  | 51 | 58 |
| Wu *et al*[23] | 1999 | Taiwan | 80 | 239 | 21 |  | 2.1 | 0 |  | 15.5 | 14.3 |  | 59.3 | 40.9 |
| Hanazaki *et al*[11] | 2001 | Japan | 70 | 283 | 103 |  | 6 | 9.7 |  | 23.3 | 28.2 |  | 40 | 42.2 |
| Yeh *et al*[12] | 2004 | Taiwan | 70 | 398 | 34 |  | 7.7 | 10.5 |  | N/A | N/A |  | 32.1 | 39.6 |
| Ferrero *et al*[13] | 2005 | Italy | 70 | 177 | 64 |  | 9.6 | 3.1 |  | 42.4 | 23.41 |  | 32.3 | 48.6 |
| Zhou *et al*[61] | 2006 | China | 65 | 125 | 54 |  | 2.4 | 0 |  | N/A | N/A |  | 38.6 | 50.1 |
| Kondo *et al*[14] | 2008 | Japan | 70 | 210 | 109 |  | 2.9 | 3.7 |  | 43.8 | 41.3 |  | NA | NA |
| Kaibori *et al*[15] | 2009 | Japan | 70 | 333 | 155 |  | 4 | 3 |  | 19 | 18 |  | 57.3 | 54.6 |
| Oishi *et al*[16] | 2009 | Japan | 75 | 502 | 64 |  | 1 | 2 |  | 19 | 22 |  | 64 | 58 |
| Huang *et al*[33] | 2009 | China | 70 | 268 | 67 |  | 1.1 | 1.5 |  | 4.5 | 9 |  | 31.4 | 43.21 |
| Mirici-Cappa *et al*[34] | 2010 | Italy | 70 | 142 | 43 |  | N/A | N/A |  | N/A | N/A |  | 32.4 | 44.8 |
| Tsujita *et al*[17] | 2010 | Japan | 75 | 77 | 23 |  | 1 | 0 |  | N/A | N/A |  | 832 | 702 |
| Portolani *et al*[35] | 2011 | Italy | 70 | 276 | 175 |  | 4.3 | 3.4 |  | 16.7 | 16 |  | N/A | N/A |
| Yamada *et al*[24] | 2012 | Japan | 80 | 267 | 11 |  | 0 | 0 |  | 3.3 (LF) | 0 (LF) |  | 43 | 26 |
| Tsujita *et al*[25] | 2012 | Japan | 80 | 385 | 23 |  | 0.8 | 4.3 |  | N/A | N/A |  | 84.8 | 95.7 |
| Nishikawa *et al*[19] | 2013 | Japan | 75 | 206 | 92 |  | N/A | N/A |  | 15.5 | 16.3 |  | 64.4 | 43 |
| Hirokawa *et al*[59] | 2013 | Japan | 70 | 120 | 100 |  | 2 | 2 |  | 35 | 32 |  | 64 | 56 |
| Ide *et al*[20] | 2013 | Japan | 75 | 192 | 64 |  | 3.1 | 3.1 |  | 29 | 33 |  | 68 | 59 |
| Ueno *et al*[21] | 2013 | Japan | 75 | 186 | 66 |  | 1 | 0 |  | 19 | 26 |  | N/A | N/A |
| Taniai *et al*[64] | 2013 | Japan | 75 | 353 | 63 |  | 2.8 | 6.3 |  | 22.9 | 30.2 |  | 46.6 | 40.2 |
| Wang *et al*[63] | 2014 | China | 70 | 152 | 56 | 　 | 1.3 | 3.6 | 　 | 47.4 | 53.6 | 　 | N/A | N/A |

1Represents significant difference; 2Represents OS at 3 years. Y: Younger patients; E: Elderly patients; OS: Overall survival rate; N/A: Not available; LF: Liver failure.